How to Prepare for the 2025-2026 ISO 10993 Standard Updates

Navigating the 2025-2026 ISO 10993 Updates: A Proactive Biocompatibility Strategy ================================================================================== With significant updates to the ISO 10993 series of biocompatibility standards anticipated around 2025-2026, medical device manufacturers are navigating a period of regulatory transition. Developing a biocompatibility evaluation strategy for a new device requires balancing compliance with currently recognized standards while anticipating future requirements from global regulatory bodies like the FDA. A forward-looking approach is essential to avoid delays and ensure a smooth review process. A robust biocompatibility strategy must pivot from a simple checklist of biological tests to a comprehensive, risk-based framework. This modern approach, emphasized in recent FDA guidance and expected in future ISO 10993 revisions, prioritizes a deep understanding of device materials through chemical characterization and toxicological risk assessment. By proactively adopting this methodology, manufacturers can build a flexible and defensible submission that is prepared for the evolving landscape, justifying the evaluation strategy with a clear, scientific rationale. ### Key Points * **Embrace a Risk-Based Framework:** The core of a modern biocompatibility strategy is a comprehensive risk assessment, not a fixed menu of tests. The evaluation should be driven by the device materials, manufacturing processes, clinical use, and potential patient exposure. * **Prioritize Chemical Characterization:** Upcoming standards are expected to increase the emphasis on ISO 10993-18 (Chemical Characterization). A proactive strategy involves conducting thorough extractables and leachables (E&L) testing to identify and quantify potential chemical hazards. * **Leverage Toxicological Risk Assessment:** Data from chemical characterization feeds into a toxicological risk assessment (per ISO 10993-17). This can often be used to demonstrate device safety and justify forgoing certain in-vivo biological tests, aligning with the 3Rs principle (Replace, Reduce, Refine animal testing). * **Conduct Rigorous Gap Analyses for Legacy Materials:** A history of safe clinical use is valuable but no longer sufficient on its own. Manufacturers must perform a formal gap analysis comparing existing material data against current standards to determine if new characterization or testing is necessary. * **Utilize the Q-Submission Program:** For novel materials or evaluation strategies that deviate from traditional testing, the FDA's Q-Submission program is an invaluable tool. It allows sponsors to gain early feedback on their Biological Evaluation Plan (BEP), significantly de-risking the final submission. * **Document Everything with a Clear Rationale:** The Biological Evaluation Plan (BEP) and final Biological Evaluation Report (BER) must tell a clear, logical story. Every decision—especially the decision *not* to perform a test—must be scientifically justified and documented. ## Understanding the Shift in Biocompatibility Evaluation Historically, biocompatibility was often treated as a checklist. A manufacturer would look at the matrix in ISO 10993-1, identify the required biological tests based on the nature and duration of body contact (e.g., cytotoxicity, sensitization, irritation), and conduct them. The modern approach, strongly encouraged by the FDA and reflected in the evolution of the ISO 10993 standards, is a more holistic and scientific process. It is an "information-first" methodology, where the goal is to thoroughly understand the device and its materials *before* resorting to biological testing. This shift is rooted in several key principles: 1. **Top-Down Risk Assessment:** The evaluation begins with a comprehensive assessment of the finished medical device, its materials, its manufacturing and sterilization processes, and its intended clinical use. The focus is on identifying potential biological risks from first principles. 2. **Material-Centric Evaluation:** Instead of just testing the final device, the focus is on understanding the chemical constituents of its materials and any residuals from manufacturing (e.g., processing aids, sterilant residues). 3. **Chemistry as a Predictive Tool:** The central idea is that if you can identify and quantify every chemical that could potentially be released from a device, and you can demonstrate that the exposure levels of these chemicals are below established safety thresholds, you can argue that the device is biologically safe without extensive animal testing. This evolution requires a change in mindset and a more integrated approach, involving material scientists, chemists, toxicologists, and regulatory professionals from the earliest stages of device development. ## Structuring a Flexible Biological Evaluation Plan (BEP) for the Transition The Biological Evaluation Plan (BEP) is the foundational document for your entire biocompatibility strategy. During this transitional period, the BEP must be structured to be robust enough for current requirements while being flexible enough for anticipated changes. This means building a strong scientific rationale that does not solely rely on the results of a standard battery of tests. A forward-looking BEP should be structured around the following steps: #### Step 1: Comprehensive Device and Material Description This section goes beyond a simple list of materials. It should include: * **Material Composition:** Detailed specifications for all patient-contacting materials, including suppliers and any colorants or additives. * **Manufacturing Processes:** A description of all processes that could leave residues on the device, such as machining oils, mold release agents, cleaning agents, and sterilization methods. * **Intended Clinical Use:** A precise description of the nature of body contact (e.g., surface, implant), duration (limited, prolonged, permanent), and patient population. #### Step 2: Identification of Biological Risks from ISO 10993-1 Based on the device description, systematically identify all potential biological risks listed in ISO 10993-1. For each potential risk (e.g., cytotoxicity, systemic toxicity, genotoxicity), the plan should state how it will be evaluated. #### Step 3: Justification of the Evaluation Strategy (The Core of the Plan) This is the most critical section. Here, the BEP must justify the chosen path for evaluating each identified risk. To build in flexibility, this section should heavily lean on a chemical- and risk-based approach. * **Leveraging Existing Data:** The plan should first describe a thorough literature search for data on the specific materials used. This includes historical clinical use, data from other legally marketed devices, and published scientific studies. * **Planning for Chemical Characterization (ISO 10993-18):** The BEP should outline a plan for exhaustive chemical characterization, typically through extractables and leachables (E&L) testing under conditions that simulate clinical use. * **Planning for Toxicological Risk Assessment (ISO 10993-17):** The plan must state that the results of the E&L testing will be used to conduct a toxicological risk assessment. A qualified toxicologist will assess the identified chemical compounds against known safety thresholds to determine if they pose an unacceptable risk. * **Rationale for Omitting Tests:** If the toxicological risk assessment concludes that all chemical exposures are within safe limits, the BEP can present a formal justification for why certain biological tests (e.g., chronic toxicity, genotoxicity) are not scientifically necessary. The rationale must be clear, data-driven, and directly address the specific biological endpoint. By structuring the BEP this way, the strategy is not dependent on a specific version of a standard. Instead, it is based on fundamental scientific principles of risk assessment that are universally accepted by regulators. ## Conducting a Gap Analysis for Legacy Materials Many manufacturers use materials with a long history of safe clinical use. While this history is valuable, regulatory bodies now expect modern data to substantiate safety claims, particularly for devices with significant patient contact. A formal gap analysis is the best practice for assessing these legacy materials. The process involves these key steps: 1. **Compile Existing Information:** Gather all available documentation for the material. This includes original supplier specifications, master files, any historical biocompatibility test reports (even if decades old), and post-market surveillance data related to adverse biological responses. 2. **Benchmark Against Current Standards:** Create a table or checklist comparing the available information against the requirements of the *currently recognized* versions of the ISO 10993 standards. Key areas to scrutinize include: * **ISO 10993-18 (Chemical Characterization):** Is there any E&L data? Was it generated using modern, sensitive analytical techniques? Does it account for manufacturing residuals and sterilants? * **ISO 10993-17 (Toxicological Risk Assessment):** Has a formal toxicological risk assessment ever been conducted on the material's chemical constituents? * **Other Endpoints:** Were historical tests conducted to GLP (Good Laboratory Practice) standards? Do the reports contain sufficient detail to be considered valid today? 3. **Identify and Risk-Assess the Gaps:** The output of the benchmark will be a list of gaps. For example, "No E&L data available" or "Sensitization study was conducted in 1995 to a non-GLP standard." Each gap must be assessed based on the risk profile of the device. A missing E&L profile for a permanent implant is a high-risk gap; a non-GLP irritation study for a limited-contact surface device may be a lower-risk gap. 4. **Develop a Proactive Testing Plan:** Based on the risk assessment, create a plan to fill the critical gaps. The highest priority is often generating robust chemical characterization data, as this information can be used to address multiple biological endpoints through a toxicological risk assessment. Proactively conducting this testing mitigates the risk of major questions and submission delays down the line. ## Strategic Considerations and the Role of Q-Submission When a biocompatibility strategy relies heavily on chemical characterization and toxicological risk assessment to justify omitting traditional in-vivo tests, it represents a departure from historical, checklist-based approaches. While this is the direction the industry is moving, it can still raise questions during a regulatory review. This is where the FDA's Q-Submission program is an essential strategic tool. By submitting the Biological Evaluation Plan (BEP) as part of a Pre-Submission (Pre-Sub), a manufacturer can get direct feedback from the FDA on their proposed evaluation strategy *before* committing significant time and resources to testing. A Q-Submission is most valuable when: * Introducing a novel material with limited biocompatibility history. * Proposing to use a chemical characterization and risk assessment approach in lieu of long-term animal studies for an implantable device. * Justifying the use of a legacy material based on a combination of historical data and a limited set of new characterization tests. Presenting a well-reasoned BEP to the FDA demonstrates a proactive and scientifically sound approach. The feedback received can be used to refine the plan, providing a high degree of confidence that the final data package will meet the agency's expectations under relevant regulations, such as those found under 21 CFR. ## Finding and Comparing Biocompatibility Testing Services Providers Successfully executing a modern, risk-based biocompatibility strategy requires a laboratory partner with deep expertise that extends beyond routine biological testing. When selecting a provider, sponsors should look for a partner who can act as a consultant, not just a testing facility. Key capabilities to look for in a provider include: * **Integrated Services:** A lab that offers both state-of-the-art chemical characterization (E&L) and a full suite of in-vivo and in-vitro biological testing under one roof can ensure a seamless evaluation process. * **Expert Toxicologists:** The provider should have on-staff, board-certified toxicologists who are experienced in writing risk assessments for medical devices and defending them to regulators. * **Regulatory Acumen:** Look for a team that is up-to-date on the latest FDA guidance documents and the anticipated changes to the ISO 10993 series. They should be able to help you design a testing plan that is both scientifically sound and regulatorily robust. * **Experience with Q-Submissions:** A partner who has helped other clients prepare for and participate in Q-Submissions can provide invaluable guidance on how to best present your strategy to the FDA. Comparing providers on these criteria—not just on price—is critical to de-risking your submission and ensuring a successful outcome. > To find qualified vetted providers [click here](https://cruxi.ai/regulatory-directories/biocompatibility_testing) and request quotes for free. ## Key FDA references When developing a biocompatibility evaluation strategy, sponsors should refer to the latest official documents and standards recognized by the FDA. While specific guidances can be device-dependent, the following are broadly applicable references: * FDA Guidance: Use of International Standard ISO 10993-1, 'Biological evaluation of medical devices - Part 1: Evaluation and testing within a risk management process'. * FDA's Q-Submission Program guidance. * 21 CFR Part 807, Subpart E – Premarket Notification Procedures (for general 510(k) context). Sponsors should always consult the FDA's website for the most current versions of guidance documents and a list of recognized consensus standards. *** *This article is for general educational purposes only and is not legal, medical, or regulatory advice. For device-specific questions, sponsors should consult qualified experts and consider engaging FDA via the Q-Submission program.* --- *This answer was AI-assisted and reviewed for accuracy by Lo H. Khamis.*